SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike Ankley who wrote (3360)7/18/1998 4:57:00 AM
From: Mike Ankley   of 5402
 
Green Cross assigned U.S. patent 4,423,061
Perfluorocycloamine emulsion preparation
patents.uspto.gov

Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved.

------------------------------------------------------------------------
Abstract
------------------------------------------------------------------------
A perfluorocycloamine emulsion preparation having oxygen carrying ability containing a perfluorocycloamine of the general formula: ##STR1## wherein any position may optionally be substituted with a perfluoromethyl group as an oxygen carrying component.

Cheers

Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News